• Clinical Insights

September 2023 drug trend report

Sep 1st, 2023

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market.

Brand name drug launches*


  • Indicated for: Treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
  • Dosage form: Extended-release injectable.
  • Status: Genoa Healthcare has been selected to participate in the Brixadi™ limited distribution network. Brixadi™ will be available at select Genoa pharmacies in early September, with availability at additional locations soon to follow. Please reach out to your local Genoa pharmacist for more information.

Zurzuvae™ (zuranolone)

  • Indicated for: Treatment of depressive symptoms in women with post-partum depression.
  • Dosage form: Once-daily, oral, 14-day medicine.
  • Status: Expected fourth quarter of 2023.

Generic drug launches*

Spiriva® HandiHaler (Tiotropium Bromide)

  • Indicated for: Controlling symptoms of chronic obstructive pulmonary disease (COPD).
  • Status: Available now.

Kombiglyze (Saxagliptin-Metformin)

  • Indicated for: Controlling high blood sugar (hyperglycemia) in adults with type 2 diabetes.
  • Status: Available now.

Onglyza (Saxagliptin)

  • Indicated for: Controlling high blood sugar (hyperglycemia) in people with type 2 diabetes.
  • Status: Available now.

Current drug shortages*


Diclofenac sodium 1% topical gel

  • Indicated for: Treatment of acute pain or osteoarthritis.
  • Status: Recovery TBD.
  • Alternatives: Ask your Genoa pharmacist for alternative options.

*Information on this page was accurate at the time of posting. Shortage recovery dates are only estimates. These estimates are based on the distribution information that Genoa has access to.

Recent Posts

  • Blog Post
Partnering with ACT teams to make an even bigger impact

Genoa Healthcare® pharmacist Julie R. has seen firsthand the impact that severe and persistent mental illness can have on a person. For one of her consumers living with schizophrenia, the...

  • Blog Post
National Prevention Week: Genoa pharmacy teams put training into action to support consumers living with substance use disorder

When she heard a woman down the street from her pharmacy became unresponsive after using opioids, Genoa Healthcare® Pharmacist Kristen Pyland leveraged her training and quick thinking to help save...

  • Blog Post
  • Webinar
For consumers living with Tardive Dyskinesia, Genoa Healthcare’s Clinical Assistance Program offers personalized support

Tardive Dyskinesia – a neurological disorder linked to prolonged use of antipsychotic medications – impacts over 600,000 individuals each year. Did you know that 50% of consumers taking TD medication...

  • Blog Post
A foundation to build on: 3 ways an engaged pharmacy partner helps you deliver whole-person health

A recent survey found that nearly 60% of behavioral health, primary care and complex care providers reported that their organization currently offered or had plans to begin offering integrated care...